| Code | CSB-RA002831MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Meplazumab, targeting BSG (Basigin), also known as CD147 or EMMPRIN (Extracellular Matrix Metalloproteinase Inducer). BSG is a transmembrane glycoprotein belonging to the immunoglobulin superfamily that plays crucial roles in multiple physiological and pathological processes. It functions as a receptor that stimulates matrix metalloproteinase production, facilitates lactate transport, and mediates cell-cell interactions. BSG is highly expressed in various malignancies where it promotes tumor invasion, metastasis, and angiogenesis. Additionally, BSG has gained significant attention as a host receptor for SARS-CoV-2 viral entry and is implicated in inflammatory diseases, making it a valuable therapeutic target.
Meplazumab is a humanized IgG2 monoclonal antibody that specifically binds to BSG and has been investigated for its potential in treating COVID-19 by blocking viral entry. This biosimilar antibody provides researchers with a reliable tool for investigating BSG-mediated signaling pathways, studying virus-host interactions, exploring tumor microenvironment dynamics, and evaluating therapeutic strategies targeting BSG in oncology and infectious disease research.
There are currently no reviews for this product.